<DOC>
	<DOCNO>NCT00274924</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving rituximab together combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study well give rituximab together combination chemotherapy work treat patient stage II , stage III , stage IV diffuse large B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Combination Chemotherapy Treating Patients With Stage II , Stage III , Stage IV Diffuse Large B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 2-year progression-free survival ( PFS ) rate treatment rituximab , ifosfamide , carboplatin , etoposide ( R-ICE ) patient bulky stage II stage III IV diffuse large B-cell non-Hodgkin 's lymphoma remain positron emission tomography ( PET ) -positive 3 course rituximab , cyclophosphamide , vincristine , doxorubicin hydrochloride , prednisone . Secondary - Determine proportion mid-treatment PET-positive patient become PET-negative 4 course R-ICE . - Determine PFS mid-treatment PET-negative patient treat regimen . - Determine overall survival patient treat regimen . - Determine toxicity regimens patient . OUTLINE : - Rituximab Combination Chemotherapy ( R-CHOP : R= Rituximab , C= Cyclophosphamide , H= Doxorubicin Hydrochloride ( Hydroxydaunomycin ) , O= Vincristine Sulfate ( Oncovin ) , P= Prednisone ) : Patients receive rituximab IV , cyclophosphamide IV , doxorubicin hydrochloride IV , vincristine IV day 1 , oral prednisone daily day 1-5 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients undergo fludeoxyglucose F18 positron emission tomography ( PET ) scan conventional restaging course 3 . Based PET result , patient assign 1 2 treatment group . - Group I ( PET negative ) : Patients receive 2 course R-CHOP absence disease progression unacceptable toxicity . - Group II ( PET positive ) : Patients receive Rituximab 375 mg/m2 IV Day 1 , Ifosfamide 5000 mg/m2 IV 24 hour Day 2 , Carboplatin AUC 5 ( max : 800 mg ) IV Day 2 , Etoposide 100 mg/m2 IV Days 1 , 2 , 3 ( R-ICE ) , Mesna 5000 mg/m2 IV 24 hour Day 2 , Filgrastim 5 mcg/kg/day subcutaneous ( SC ) Day 4 absolute neutrophil count ( ANC ) recovery every 14 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 10 year date study entry . ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>INCLUSION CRITERIA : Diffuse large Bcell nonHodgkin 's lymphoma Bulky stage II ( bulk define lesion ≥ 10 cm ) stage III IV disease The following lymphoma type exclude : Primary central nervous system lymphoma Transformed lowgrade lymphoma ( prior history lowgrade lymphoma clear presence lowgrade lymphoma histologic section ) Primary mediastinal Bcell lymphoma testicular lymphoma ( consolidative radiotherapy usually indicate ) Immunodeficiencyrelated lymphoma ( i.e. , organ bone marrow transplant ) Measurable disease Patient must least one objective measurable disease site ( i.e. , measurable least 2 perpendicular parameter ) Measurable disease liver require liver site lymphoma involvement Abnormal positron emission tomography scan constitute evaluable disease , unless verify CT scan appropriate image Eastern Cooperative Oncology Group ( ECOG ) performance status 03 For patient &gt; 50 year age , normal ejection fraction ECHO Multigated Acquisition Scan ( MUGA ) require within 6 week prior registration Absolute neutrophil count ≥ 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Creatinine &lt; 2.0 mg/dL Bilirubin &lt; 2 mg/dL ( may 3.0 mg/dL due liver involvement lymphoma ) EXCLUSION CRITERIA : Prior chemotherapy radiation therapy lymphoma Prior anthracyclines platinum compound use systemic chemotherapy Prior radiation therapy mediastinum ≥ 25 % bone marrow Concurrent pentostatin trastuzumab ( Herceptin® ) Pregnant nursing Prior malignancy within past 5 year unless situ OR treat curative intent AND patient remain relapsefree HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>